184 related articles for article (PubMed ID: 37152309)
41. Recovery fulminant hepatitis A in systemic juvenile idiopathic arthritis patient treated with tocilizumab: a case report.
Kudsi M; Alghawe F; Hamsho S
Ann Med Surg (Lond); 2023 Oct; 85(10):5163-5166. PubMed ID: 37811054
[TBL] [Abstract][Full Text] [Related]
42. Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study.
Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Takeuchi T; Nagai K; Son Y; Amuro H; Onishi A; Jinno S; Hara R; Katayama M; Yamamoto K; Kumanogoh A; Hirao M
Clin Rheumatol; 2020 Sep; 39(9):2563-2572. PubMed ID: 32162152
[TBL] [Abstract][Full Text] [Related]
43. The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives.
Toplak N; Blazina Š; Avčin T
Drug Des Devel Ther; 2018; 12():1633-1643. PubMed ID: 29922038
[TBL] [Abstract][Full Text] [Related]
44. Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
Lee PY; Schulert GS; Canna SW; Huang Y; Sundel J; Li Y; Hoyt KJ; Blaustein RB; Wactor A; Do T; Halyabar O; Chang MH; Dedeoglu F; Case SM; Meidan E; Lo MS; Sundel RP; Richardson ET; Newburger JW; Hershfield MS; Son MB; Henderson LA; Nigrovic PA
Ann Rheum Dis; 2020 Feb; 79(2):225-231. PubMed ID: 31707357
[TBL] [Abstract][Full Text] [Related]
45. Inflammatory Bowel Disease in Children With Systemic Juvenile Idiopathic Arthritis.
Maller J; Fox E; Park KT; Paul SS; Baszis K; Borocco C; Prahalad S; Quartier P; Reinhardt A; Schonenberg-Meinema D; Shipman-Duensing L; Terreri MT; Simard J; Lavi I; Chalom E; Hsu J; Zisman D; Mellins ED;
J Rheumatol; 2021 Apr; 48(4):567-574. PubMed ID: 32541073
[TBL] [Abstract][Full Text] [Related]
46. Effective therapy of tocilizumab on systemic juvenile idiopathic arthritis-associated refractory macrophage activation syndrome.
Wu J; Sun L; Tang X; Zheng Q; Guo L; Xu L; Li Y; Lu M
Mod Rheumatol; 2022 Oct; 32(6):1114-1121. PubMed ID: 34971386
[TBL] [Abstract][Full Text] [Related]
47. Treatment of systemic JIA: When do we need a biologic? Real world data of a single center.
Adiguzel Dundar H; Acari C; Turkucar S; Unsal E
Mod Rheumatol; 2021 May; 31(3):684-690. PubMed ID: 32343644
[TBL] [Abstract][Full Text] [Related]
48. Differentiating macrophage activation syndrome in systemic juvenile idiopathic arthritis from other forms of hemophagocytic lymphohistiocytosis.
Lehmberg K; Pink I; Eulenburg C; Beutel K; Maul-Pavicic A; Janka G
J Pediatr; 2013 Jun; 162(6):1245-51. PubMed ID: 23333131
[TBL] [Abstract][Full Text] [Related]
49. Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-γ.
Put K; Avau A; Brisse E; Mitera T; Put S; Proost P; Bader-Meunier B; Westhovens R; Van den Eynde BJ; Orabona C; Fallarino F; De Somer L; Tousseyn T; Quartier P; Wouters C; Matthys P
Rheumatology (Oxford); 2015 Aug; 54(8):1507-17. PubMed ID: 25767156
[TBL] [Abstract][Full Text] [Related]
50. Reasons for Initiating Canakinumab among Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still's Disease in the U.S. Real-World Settings.
Hur P; Yi E; Ionescu-Ittu R; Manceur AM; Lomax KG; Cammarota J; Xie J; Gautam R; Nakasato P; Sanghera N; Kim N; Grom AA
Rheumatol Ther; 2022 Feb; 9(1):265-283. PubMed ID: 34874547
[TBL] [Abstract][Full Text] [Related]
51. Sequential Tocilizumab and Tofacitinib Treatment for Systemic Juvenile Idiopathic Arthritis: a Case Report.
Zhang Y; Ru J; Zhang J
Rheumatol Ther; 2023 Feb; 10(1):293-300. PubMed ID: 36443570
[TBL] [Abstract][Full Text] [Related]
52. Canakinumab for the treatment of active systemic juvenile idiopathic arthritis.
Orrock JE; Ilowite NT
Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1015-24. PubMed ID: 27367267
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of clinical outcomes in systemic juvenile idiopathic arthritis patients treated with biological agents in Turkey: the TURSIS study.
Sozeri B; Demir F; Barut K; Atalay E; Pac Kisaarslan A; Özdel S; Altuğ Gücenmez Ö; Makay B; Aktay Ayaz N; Haşlak F; Sağ E; Yıldız M; Kaya Akça Ü; Adroviç A; Bilginer Y; Poyrazoğlu H; Ünsal E; Kasapçopur Ö; Özen S
Clin Exp Rheumatol; 2024 Jan; 42(1):194-201. PubMed ID: 37497697
[TBL] [Abstract][Full Text] [Related]
54. Withdrawal of biologic therapy in juvenile idiopathic arthritis due to remission: predictors of flare and outcomes.
Tanatar A; Akgün Ö; Çağlayan Ş; Bağlan E; Otar Yener G; Öztürk K; Çakan M; Sönmez HE; Sözeri B; Aktay Ayaz N
Expert Opin Biol Ther; 2023 Mar; 23(3):305-313. PubMed ID: 36825474
[TBL] [Abstract][Full Text] [Related]
55. Biomarkers in Systemic Juvenile Idiopathic Arthritis, Macrophage Activation Syndrome and Their Importance in COVID Era.
Ailioaie LM; Ailioaie C; Litscher G
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361547
[TBL] [Abstract][Full Text] [Related]
56. Nonspecific interstitial pneumonia in refractory systemic juvenile idiopathic arthritis responded to tocilizumab treatment.
Sukharomana M; Udomittipong K; Ruangchira-Urai R; Charuvanij S
Asian Pac J Allergy Immunol; 2022 Jun; 40(2):172-176. PubMed ID: 31837211
[TBL] [Abstract][Full Text] [Related]
57. State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis.
El Jammal T; Sève P; Gerfaud-Valentin M; Jamilloux Y
Expert Opin Pharmacother; 2021 Feb; 22(2):205-218. PubMed ID: 32967471
[TBL] [Abstract][Full Text] [Related]
58. Efficacy of anakinra treatment in pediatric rheumatic diseases: Our single-center experience.
Demir F; Gürler E; Sözeri B
Arch Rheumatol; 2022 Sep; 37(3):435-443. PubMed ID: 36589607
[TBL] [Abstract][Full Text] [Related]
59. Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis.
Ruperto N; Brunner HI; Ramanan AV; Horneff G; Cuttica R; Henrickson M; Anton J; Boteanu AL; Penades IC; Minden K; Schmeling H; Hufnagel M; Weiss JE; Pardeo M; Nanda K; Roth J; Rubio-Pérez N; Hsu JC; Wimalasundera S; Wells C; Bharucha K; Douglass W; Bao M; Mallalieu NL; Martini A; Lovell D; Benedetti F;
Rheumatology (Oxford); 2021 Oct; 60(10):4568-4580. PubMed ID: 33506875
[TBL] [Abstract][Full Text] [Related]
60. Factors and glucocorticoid usage affecting the prognosis of systemic juvenile idiopathic arthritis.
Paç Kısaarslan A; Özdemir Çiçek S; Şahin N; Başol M; Doğantan Ş; Taşkın SN; Poyrazoğlu MH
Pediatr Int; 2021 Dec; 63(12):1424-1432. PubMed ID: 33760311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
